Evaluating patient discomfort, anxiety, and fear before and after ranibizumab intravitreous injection for wet age-related macular degeneration.
Chua
Paul Yih Seng
PY
Princess Alexandra Eye Pavilion, University of Edinburgh, 27/1 St Patrick Sq, Edinburgh EH8 9EY, Scotland. chuayihseng@gmail.com
Mitrut
Izabela
I
Armbrecht
Ana-Marie
AM
Vani
Archana
A
Aslam
Tariq
T
Dhillon
Baljean
B
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D001007:Anxiety / Q000523:psychology*; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D005239:Fear / Q000523:psychology*; D005260:Female; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000188:drug therapy*; D008297:Male; D010147:Pain Measurement; D017060:Patient Satisfaction; D010361:Patients / Q000523:psychology*; D011446:Prospective Studies; D000069579:Ranibizumab; D011795:Surveys and Questionnaires; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab